Skip to content

#PTSD

11 AugTue
  1. MAPS62

    MAPS responds to report that Resilient has resubmitted its MDMA therapy NDA to FDA

    MAPS said it welcomed a new FDA evaluation after an August 9 report by Psychedelic Alpha that Resilient Pharmaceuticals (formerly MAPS PBC and Lykos Therapeutics) had resubmitted its new drug application for MDMA-assisted therapy for PTSD. The resubmission follows the Complete Response Letter issued on August 9, 2024, which recommended additional research on durability of response, safety characterisation and steps to minimise potential bias, and MAPS noted it comes without a new Phase 3 study. MAPS, which funded the clinical research completed in 2022 and says it has no active role in Resilient's drug development, also pointed to the FDA's final July 2026 guidance, Psychedelic Drugs: Considerations for Clinical Investigations, as reflecting approaches it developed with the agency.